Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours Β· Estimated delivery Aug 9 - Aug 14
OptumRx PA criteria for Zepbound Standard OptumRx PA for Zepbound (obesity indication) typically requires: BMI 30 or higher, or BMI 27 with documented comorbidity (hypertension, type 2 diabetes, dyslipidemia, OSA) Participation in a structured weight-management program, typically 3 to 6 months of documented engagement Absence of contraindications (personal or family history of MTC, MEN 2) Attestation of medical necessity by the prescribing physician For step-therapy plans, prior trial of preferred GLP-1 alternative Initial approval is generally 6 months, with reauthorization requiring documented weight loss of 5% or more from baseline
In addition to regulating epigenetic methylase activity, metabolism also affects epigenetic enzymes involved in demethylation in cancer cells
Rash as a Side Effect of Semaglutide: A Real-world Evidence Study. Journal of Diabetes and Its Complications, 30(4), 279-285
Despite the declines, GLP-1 users reported a continued desire to consume processed foods, sodas, refined grains and beef
